Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 7:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 74 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Half-normal saline Clear all
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Phase 1 Trial of PfSPZ Vaccine in Healthy Adults to Determine Safety, Tolerability and Efficacy Against Heterologous CHMI

NCT05604521
View directory record Official record
Conditions
Malaria, Malaria,Falciparum
Interventions
PfSPZ Vaccine, PfSPZ Challenge (7G8), Normal Saline
Biological · Other
Lead sponsor
Sanaria Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 24, 2024 · Synced Sep 11, 2026, 7:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Biology of Resilience

NCT01011465
View directory record Official record
Conditions
Oxytocin, Placebo
Interventions
intranasal oxytocin, Placebo, Social support, No Social Support
Drug · Behavioral
Lead sponsor
Harvard School of Public Health (HSPH)
Other
Eligibility
22 Years to 65 Years
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 25, 2012 · Synced Sep 11, 2026, 7:14 AM EDT
Completed Phase 4 Interventional Results available

Study of EXPAREL in Patients Undergoing Breast Augmentation

NCT01582490
View directory record Official record
Conditions
Mammoplasty, Postoperative Pain
Interventions
Instillation - EXPAREL, Infiltration - EXPAREL
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Brighton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2014 · Synced Sep 11, 2026, 7:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

PTH And Calcium Responses to Exercise in Older Adults Experiment 2 (PACE Sr. 2)

NCT02580604
View directory record Official record
Conditions
Osteoporosis
Interventions
Calcium Chloride/Calcium Gluconate, Half-Normal Saline
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
60 Years to 80 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Sep 11, 2026, 7:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Reducing Postoperative Catheterization

NCT03009968
View directory record Official record
Conditions
Urinary Retention, Urinary Incontinence, Pelvic Organ Prolapse, Urinary Tract Infections
Interventions
Post-void residual free voiding trial
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 18, 2018 · Synced Sep 11, 2026, 7:14 AM EDT
Completed Phase 2 Interventional Results available

Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)

NCT01594827
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Inhaled Vancomycin, Placebo (Sterile Water), Rifampin, Trimethoprim/Sulfamethoxazole (TMP/SMX), Doxycycline, Mupirocin Intranasal Creme, 4% chlorhexidine gluconate liquid skin cleanser
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Sep 11, 2026, 7:14 AM EDT
Completed Phase 4 Interventional

Effectiveness Study of MIST Therapy After Cosmetic Surgery Procedures of the Face and Body

NCT01206855
View directory record Official record
Conditions
Cosmetic Surgery
Interventions
MIST Therapy, Standard Postoperative Incision Care
Device · Other
Lead sponsor
Celleration, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
3,440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 7, 2014 · Synced Sep 11, 2026, 7:14 AM EDT
Completed Phase 4 Interventional Results available

Volume Versus Concentration: Clinical Effectiveness of Single Shot Quadrates Lumborum Block Using Either a High Volume/Low Concentration or Low Volume/High Concentration Injectate for Total Hip Arthroplasty.

NCT04259645
View directory record Official record
Conditions
Acute Pain
Interventions
Drug: Bupivacaine 0.375% 20 mL, Drug: Bupivacaine 0.375% diluted to 0.1875%
Drug
Lead sponsor
Anna Uskova
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Sep 11, 2026, 7:14 AM EDT
Terminated Phase 2 Interventional Results available

A Safety and Effectiveness Study of Intraspinal Gabapentin (MDT2004) for the Treatment of Chronic Pain

NCT00414466
View directory record Official record
Conditions
Chronic Intractable Pain
Interventions
Intraspinal Gabapentin
Drug
Lead sponsor
MedtronicNeuro
Industry
Eligibility
18 Years to 70 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
14
States / cities
Little Rock, Arkansas • Napa, California • Sarasota, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2013 · Synced Sep 11, 2026, 7:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Optimization of a Tenofovir Enema for HIV Prevention

NCT02750540
View directory record Official record
Conditions
HIV Prevention
Interventions
Tenofovir enema, Saline enema
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
3
States / cities
Los Angeles, California • Baltimore, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Sep 11, 2026, 7:14 AM EDT
Completed Not applicable Interventional Results available

Aerosolized Albuterol Use in Severe BPD

NCT02766673
View directory record Official record
Conditions
Severe Bronchopulmonary Dysplasia
Interventions
Albuterol Sulfate, Sterile Saline
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 1 Year
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 11, 2026, 7:14 AM EDT
Completed Phase 2 Interventional

Evaluation of Safety & Efficacy of BIO-11006 Inhalation Solution in Patients With ARDS

NCT03202394
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
BIO-11006, Placebo
Drug
Lead sponsor
BioMarck Pharmaceuticals, Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
Chicago, Illinois • Chapel Hill, North Carolina • Winston-Salem, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2020 · Synced Sep 11, 2026, 7:14 AM EDT
Terminated Not applicable Interventional Results available

Glycemic Effects of Morning Only, Evening Only or Twice Daily Insulin Glargine in Patients With Type 1 Diabetes

NCT00869414
View directory record Official record
Conditions
Type 1 Diabetes, Hypoglycemia
Interventions
Evening only administration of insulin glargine, Morning only administration of insulin glargine, split dose insulin glargine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 90 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Sep 11, 2026, 7:14 AM EDT
Recruiting Phase 3 Interventional

Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass

NCT06096116
View directory record Official record
Conditions
Acquired Antithrombin Deficiency
Interventions
Human plasma derived antithrombin, Placebo
Drug
Lead sponsor
Octapharma
Industry
Eligibility
18 Years to 85 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
9
States / cities
Stanford, California • Miami, Florida • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 11, 2026, 7:14 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

A Pilot Study on the Use of Platelet Rich Plasma (PRP) for Facial and Hand Skin Rejuvenation

NCT03647917
View directory record Official record
Conditions
Skin Aging of Face and Hands
Interventions
Platelet Rich Plasma
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
45 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Sep 11, 2026, 7:14 AM EDT
Terminated Phase 3 Interventional

Minimal Breathing Support and Early Steroids to Prevent Chronic Lung Disease in Extremely Premature Infants (SAVE)

NCT00005777
View directory record Official record
Conditions
Bronchopulmonary Dysplasia, Respiratory Distress Syndrome, Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
Interventions
Minimal mechanical ventilation management, Routine mechanical ventilation management, Dexamethasone, Placebo
Procedure · Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
5 Minutes to 10 Days
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
13
States / cities
Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Sep 11, 2026, 7:14 AM EDT
Completed Phase 2 Interventional Results available

Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis

NCT01670565
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
Belimumab, Mycophenolate Mofetil, Placebo Infusion
Drug · Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced Sep 11, 2026, 7:14 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Pilot Study of Magnesium Infusions in Pediatric Asthma

NCT01522040
View directory record Official record
Conditions
Asthma
Interventions
Magnesium Sulfate, Placebo
Drug
Lead sponsor
University of Louisville
Other
Eligibility
2 Years to 20 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Sep 11, 2026, 7:14 AM EDT
Completed Not applicable Interventional Results available

Goal-Directed Intraoperative Fluid Management Using FloTrac© Monitoring in High-Risk Neurosurgical Patients

NCT02701582
View directory record Official record
Conditions
Intracranial Aneurysm, Brain Edema, Scoliosis, Surgery
Interventions
Phenylephrine, Epinephrine, Albumin, Voluven, Normal Saline, Packed Red Blood Cells, FloTrac Monitor
Drug · Other · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
15 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 11, 2026, 7:14 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Pharmacological Modulation of Brain Oscillations in Memory Processing

NCT05594017
View directory record Official record
Conditions
Epilepsy, Seizures, Cognitive Impairment, Mild, Memory Disorders, Memory Loss
Interventions
Scopolamine (0.4mg), Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Sep 11, 2026, 7:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Salmonella Conjugates CVD 2000: Study of Responses to Vaccination With Trivalent Salmonella Conjugate Vaccine to Prevent Invasive Salmonella Disease

NCT05525546
View directory record Official record
Conditions
Risk Reduction
Interventions
Trivalent Salmonella Conjugate Vaccine (TSCV) Full-Strength Formulation, Trivalent Salmonella Conjugate Vaccine (TSCV) Half-Strength Formulation, Trivalent Salmonella Conjugate Vaccine (TSCV) Dilutional Half-Strength Formulation, Placebo
Biological · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 49 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 11, 2026, 7:14 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study to Evaluate is ECV Success is Improved and the Side Effects Reduced With the Use of IV NTGL Versus Terbutaline

NCT02115256
View directory record Official record
Conditions
External Cephalic Version
Interventions
Intravenous Terbutaline, Intravenous Nitroglycerine
Drug
Lead sponsor
Yaakov Beilin
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Sep 11, 2026, 7:14 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Rett Syndrome With Recombinant Human IGF-1

NCT01777542
View directory record Official record
Conditions
Rett Syndrome
Interventions
Recombinant Human Insulin Growth Factor 1 (rhIGF-1), Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Years to 10 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 25, 2018 · Synced Sep 11, 2026, 7:14 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Intramyocellular Fatty Acid Trafficking in Insulin Resistance States - Effects of Intestinal Delivery of Lipids

NCT03818178
View directory record Official record
Conditions
Insulin Resistance
Interventions
Intralipid, Palm Oil Emulsion, Saline
Dietary Supplement · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Sep 11, 2026, 7:14 AM EDT